Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Abstract Background For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis. Methods A search was conducted on EMBA...
Main Authors: | Liuting Yang, Xiaoyue Jiang, Han Yan, Yingying Li, Hongchao Zhen, Bingmei Chang, Seyed Kariminia, Qin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12876-018-0772-4 |
Similar Items
-
Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01) -
Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
by: Bei Yue, et al.
Published: (2021-10-01) -
Irinotecan-Induced Steatohepatitis: Current Insights
by: Jun Han, et al.
Published: (2021-10-01) -
Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study
by: Xichao Dai, et al.
Published: (2023-08-01) -
Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
by: Jinglei Qu, et al.
Published: (2023-04-01)